SUGAR LAND, Texas – A Sugar Land biopharmaceutical company is the first in the country to receive FDA approval or a trial to treat long-haul COVID-19 with adult stem cells.
Long carriers are patients who are no longer infected with the coronavirus but who sometimes suffer from it for months.
“We actually don’t know much about this post-COVID-19 syndrome, but there are a lot of people in our community who are suffering,” said Donna Chang, president of Hope Biosciences.
The company said that during their initial three-and-a-half-month treatments, patients with persistent coughs, headaches, chronic fatigue and other symptoms responded well to cells and were able to resume normal lives. .
“We have a pretty good idea of how they work,” Chang said. “We just don’t know how well they work on long haul COVIDs. But we think it’s a good solution.
Doctors extract fat cells from the patient’s stomach in what they say is a painless procedure. Hope Biosciences then uses a patented medium, or food source, which ends up growing a billion of the patient’s stem cells which are then injected back into their bodies.
The stem cells then cause particular symptoms to hopefully provide much-needed relief to patients.
“I think that’s what these long COVD-19 carriers want,” Chang said. “They just want the chance to feel normal again. So we hope to be able to achieve this with this trial. “
Copyright 2021 by KPRC Click2Houston – All rights reserved.